Q4 2024 Incyte Corp Earnings Call Transcript
Key Points
- Incyte Corp (INCY) reported a 15% increase in total revenues for 2024, reaching $4.2 billion, demonstrating steady growth since 2020.
- Jakafi net sales grew by 8% to $2.8 billion in 2024, with growth across all indications, particularly in polycythemia vera (PV).
- Opzelura showed strong momentum with a 50% increase in revenue to $508 million, driven by new patients and refills in atopic dermatitis (AD) and vitiligo.
- The company completed a $2 billion share repurchase in 2024, maintaining a strong balance sheet with $2.2 billion in cash and no debt.
- Incyte Corp (INCY) anticipates four new product launches in 2025, including Niktimvo, which is expected to contribute significantly to revenue growth.
- The company faces risks and uncertainties that could cause actual results to differ materially from forward-looking statements.
- Incyte Corp (INCY) anticipates lower net pricing for Jakafi due to IRA-imposed price increase caps and continued growth in 340B volumes.
- Operating expenses increased, with GAAP R&D expenses rising by 5% in Q4 2024 and 14% for the full year, driven by late-stage development investments.
- SG&A expenses increased by 11% year-over-year in Q4 2024, partly due to Monjuvi-related sales and marketing expenses.
- The company expects typical Q1 dynamics to impact Opzelura net product revenue, with Q1 2025 expected to be lower than the previous quarter.
Greetings and welcome to the Incyte fourth-quarter 2024 and full-year financial and corporate update conference call webcast. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the call? Over to Ben Strain, Associate Vice President of Investor Relations. Please go ahead, Ben.
Thank you, Kevin. Good morning and welcome to Incyte's fourth-quarter and full-year 2024 earnings conference call. Before we begin, I encourage everyone to go to the investors section of our website to find the press release, related financial tables, and slides that follow today's discussion. On today's call, I'm joined by Herve, Pablo, Christiana, who will deliver the prepared remarks; Matteo and Steven will also be available for Q&A.
I would like to point out that we'll be making forward-looking statements which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
